| Market Cap | 7.25M | P/E | - | EPS this Y | - | Ern Qtrly Grth | - |
| Income | -1.97M | Forward P/E | - | EPS next Y | - | 50D Avg Chg | -5.00% |
| Sales | - | PEG | - | EPS past 5Y | - | 200D Avg Chg | -36.00% |
| Dividend | N/A | Price/Book | N/A | EPS next 5Y | - | 52W High Chg | -81.00% |
| Recommedations | - | Quick Ratio | 0.02 | Shares Outstanding | 154.31M | 52W Low Chg | 12.00% |
| Insider Own | 36.29% | ROA | -7,580.21% | Shares Float | - | Beta | -2.23 |
| Inst Own | - | ROE | - | Shares Shorted/Prior | -/- | Price | 0.05 |
| Gross Margin | - | Profit Margin | - | Avg. Volume | 116 | Target Price | - |
| Oper. Margin | - | Earnings Date | - | Volume | 100 | Change | 0.00% |
National Graphite Corp., through its subsidiary, Biotech Development Corp., operates as a biopharmaceutical risk/cost-sharing company. The company collaborates with clinical stage companies that develop new biological entities or new therapeutically platforms for the treatment of various diseases, rare diseases, and diseases with unmet needs. It is developing a drug candidate called ELAFIN, which is a human identic protein for the treatment of postoperative inflammatory complications. National Graphite Corp. has a collaboration agreement with Proteo Inc. for developing ELAFIN. The company was formerly known as Lucky Boy Silver Corporation and changed its name to National Graphite Corp. in May 2012. National Graphite Corp. was founded in 2006 and is based in Duesseldorf, Germany.